Prognostic factors and genetic markers in thymoma

Kolen, Katrien Van; Pierrache, Laurence; Heyman, Stijn; Pauwels, Patrick; Schil, Paul Van

doi:10.1111/j.1759-7714.2010.00028.x

Cited by 14 publications

(21 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because of their indolent course, diagnosis and therapy approaches have mainly been based on retrospective or descriptive epidemiological studies of thymic malignancies. Limited epidemiological studies have been focused on long-term outcomes and treatment modality in the Middle East, where the disease tends to be more prevalent (Ahmed et al, 1995;Engels, 2010;Weis et al, 2015;Van Kolen et al, 2010). The objectives of this study were to investigate the clinicopathological features, treatment modalities, and prognostic factors in order to estimate long-term outcomes for patients with thymoma and thymic carcinoma, and who have been treated at our institution over 38 years.…”

Section: Treatment Outcome and Prognostic Factors Of Malignant Thymommentioning

confidence: 99%

Treatment Outcome and Prognostic Factors of Malignant Thymoma - A Single Institution Experience

Alothaimeen

Memon

2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: Our objectives are to investigate the clinicopathological features, treatment modalities, and prognostic and prognostic factors in order to estimate long-term outcomes for patients with thymoma and thymic carcinoma at our institution. Methods: We reviewed all patients diagnosed with thymic malignancies malignancies over a period of 38 years (from 1976 to 2014). Patients were identified using a single institution database at King Faisal Specialist Hospital and Research Center (KFSH and RC), Riyadh. Demographic data, clinical staging, histopathology classification, treatment approaches, and survival data were collected. Data Analysis was performed using both the Kaplan-Meier method and Cox proportional hazards modeling. Results: The fifty-six identified patients consists of 30 females (53.6%) and 26 males (46.4%). The median age at diagnosis was 39 years. About 37% of the patients were diagnosed with myasthenia gravis (MG). There was a significant association between the WHO histologic classification and the Masaoka stage (p= 0.018). The estimated 5-year overall survival rate was 88.6% for patients with thymic malignancies. The median survival time of thymoma and thymic carcinoma was 61 and 14 months, respectively. The univariate analysis suggested that histology (thymoma versus thymic carcinoma, p= 0.044) and Masaoka stage (II-III versus IV, p= 0.048) were independent prognostic factors affecting overall survival. Histology (p = 0.044) was found to be an independent predictor of overall survival. Conclusion: The findings of this study indicates that late Masaoka-Koga staging and histology types are significantly associated with extended overall survival. Similarly, surgical resection and multimodality treatments play a significant role in thymic malignancies neoplasms therapy strategies to prolong survival rates.

show abstract

Section: Treatment Outcome and Prognostic Factors Of Malignant Thymommentioning

confidence: 99%

Treatment Outcome and Prognostic Factors of Malignant Thymoma - A Single Institution Experience

Alothaimeen

Memon

2020

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

show abstract

“…In addition, one of the three MCPyV positive tissues was classified as stage IIIB (Table ). The higher thymoma stages are considered to be more invasive . The sTAg of MCPyV was recently observed to provide cells the ability to migrate; however, in as much this applies to HPyV7 and thymic epithelial cells currently remains speculation.…”

Section: Discussionmentioning

confidence: 99%

Low prevalence of Merkel cell polyomavirus in human epithelial thymic tumors

et al. 2019

View full text Add to dashboard Cite

Background The etiology of thymic epithelial tumors is unknown. Murine polyomavirus strain PTA has been shown to induce thymomas in mice. Recently, using diverse molecular techniques, we reported the presence of human polyomavirus 7 (HPyV7) in thymic epithelial tumors. In the present study, we investigated the prevalence of Merkel cell polyomavirus (MCPyV) in thymic epithelial tumors. Methods Thirty‐six thymomas were screened for MCPyV by PCR and subsequently tested by DNA and RNA in situ hybridization and immunohistochemistry. Twenty‐six thymomas were diagnosed with myasthenia gravis (MG). Results MCPyV DNA was detected by PCR in 7 (19.4%) of the 36 thymic epithelial tumors and in six of these, the presence of MCPyV was confirmed by fluorescence situ hybridization. Of these, 3 (28.6%) revealed weak MCPyV LT‐antigen protein expression. In addition, one of the MCPyV positive thymomas tested positive for MCPyV LT RNA with RNAscope. Of interest, two out of the three thymomas that previously tested positive for MCPyV by immunohistochemistry also tested positive for HPyV7. One of the 11 MG‐negative and 2 of the 25 MG‐positive were positive for MCPyV. Conclusions MCPyV DNA and MCPyV protein expression can be detected in human epithelial thymoma; however, to a far lesser extent than HPyV7. Our data strongly indicate that because of its infrequent detection and weak expression, MCPyV is unlikely to play an important role in the etiopathogenesis of human thymomas.

show abstract

“…The World Health Organization (WHO) classifies, TETs according to their histological features including the morphology of thymic epithelial cells and number of T lymphocytes [4]. Specifically, TETs are divided into types A, B, AB mixed, and C (or thymic T carcinoma) by the WHO classification [5]. Because of the rarity of TETs, the etiological factors that induce thymoma development remain unclear.…”

Section: Introductionmentioning

confidence: 99%